Shattuck Labs, Inc. (STTK) Dividend History

Shattuck Labs, Inc. is a biotechnology company focused on developing innovative therapeutics that modulate the immune system. The company leverages its proprietary SIRPα-Fc fusion protein platform to create targeted therapies aimed at treating cancer and autoimmune diseases. Founded to advance immune-modulating agents, Shattuck Labs emphasizes precision medicine approaches in its drug development pipelines.

500 W. 5th Street, Austin, TX, 78701
Phone: 512-900-4690
Website: https://www.shattucklabs.com

Dividend History

Shattuck Labs, Inc. currently does not pay dividends

Company News

  • Shattuck Labs, a biotechnology company, announced that its CEO will present at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's lead program, SL-325, is a potential first-in-class DR3 antagonist antibody designed to treat inflammatory and immune-mediated diseases.

    GlobeNewswire Inc.
  • Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

    Seeking Alpha
  • Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.

    Zacks Investment Research
    Featured Companies: ALXO LGND NERV
  • During the last three months, 6 analysts shared their evaluations of Shattuck Labs (NASDAQ:STTK), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $16.67, a high estimate of $28.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.4%. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive Shattuck Labs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gil Blum Needham Lowers Buy $8.00 $12.00 Joseph Pantginis HC Wainwright & Co. Maintains Buy $28.00 $28.00 Gil Blum Needham Maintains Buy $12.00 $12.00 Gil Blum Needham Maintains Buy $12.00 $12.00 Joseph Pantginis HC Wainwright & Co. Maintains Buy $28.00 $28.00 Gil Blum Needham Maintains Buy $12.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Shattuck Labs. This ...Full story available on Benzinga.com

    Benzinga
Page data last updated 07/23/2025 09:29:43 UTC